

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/750,118	12/31/2003	Peter Sterling Mueller	893-2 CIP II /DIV 9765 EXAMINER	
23869 7:	590 03/02/2006			
HOFFMANN & BARON, LLP			JONES, DWAYNE C	
6900 JERICHO TURNPIKE SYOSSET, NY 11791			ART UNIT	PAPER NUMBER
ŕ			1614	
			DATE MAILED: 03/02/2000	6

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summany	10/750,118	MUELLER, PETER STERLING				
Office Action Summary	Examiner	Art Unit				
	Dwayne C. Jones	1614				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONEI	l. ely filed the mailing date of this communication. O (35 U.S.C. § 133).				
Status						
. 1) Responsive to communication(s) filed on						
	action is non-final.					
3) Since this application is in condition for allower		secution as to the merits is				
closed in accordance with the practice under E	•					
Disposition of Claims						
4)⊠ Claim(s) <u>1,3,5-7,10,11,18,19,22,23,26-28 and 31-41</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) See Continuation Sheet are subject to	restriction and/or election require	ement.				
Application Papers	·					
9) The specification is objected to by the Examiner	,					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
•	armier. Note the attached Office	rough of form 1 to 102.				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of 	s have been received. s have been received in Application ity documents have been receive (PCT Rule 17.2(a)).	on No d in this National Stage				
Attachment(s)	» П	VDTO 440)				
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary (Paper No(s)/Mail Da					
Paper No(s)/Mail Date	·—	atent Application (PTO-152)				

Application/Control Number: 10/750,118

Art Unit: 1614

Page 2

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1 and 3, drawn to a method of enhancing or stimulating neurogenesis, classified in class 514, subclass 646+.
 - II. Claims 5-7, drawn to a method of treating symptoms of Cerebral Palsy, classified in class 514, subclass 646+.
 - III. Claims 10-11, drawn to a method for the treatment of the symptoms of Torticollis, classified in class 514, subclass 646+.
 - IV. Claims 14-17, drawn to a method for the treatment of the symptoms of Dystonia, classified in class 514, subclass 646+.
 - V. Claims 18-19, drawn to a method for the treatment of the symptoms of
 Dyskinesia, classified in class 514, subclass 646+.
 - VI. Claims 22-23, drawn to a method for the treatment of the symptoms of Institutionalization and Concentration Camp Syndromes, classified in class 514, subclass 646+.
 - VII. Claims 26-28, drawn to a method for the treatment of the symptoms of Dementia, classified in class 514, subclass 646+.
 - VIII. Claims 31-32, drawn to a method for the treatment of neurological, behavioral, and cognitive disorders, classified in class 514, subclass 646+.

Application/Control Number: 10/750,118

Art Unit: 1614

IX. Claim 33, drawn to a method for the treatment of the symptoms of Sick Building Syndrome, classified in class 514, subclass 646+.

Page 3

- Claim 34, drawn to a method for the treatment of the symptoms of Gulf
 War Syndrome, classified in class 514, subclass 646+.
- XI. Claims 35-38, drawn to a method for the treatment of the symptoms of Reflex Sympathetic Dystrophy Syndrome or Complex Regional Pain Syndrome, classified in class 514, subclass 646+.
- XII. Claim 39, drawn to a method for the treatment of the symptoms of Retinitis Pigmentosa, classified in class 514, subclass 646+.
- XIII. Claim 40, drawn to a method for the treatment of the symptoms of organic brain impairments, classified in class 514, subclass 646+.
- XIV. Claim 41, drawn to a method for the treatment of the sexual disorders, classified in class 514, subclass 646+.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions I and (II-XIV) are unrelated. Inventions are unrelated if it can be shown that they different effects. In the instant case the different inventions, are each directed to treating a variety of separate and distinct diseases and symptoms of various disease states.
- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Application/Control Number: 10/750,118

Art Unit: 1614

4. Claims 1, 5, 6, 10, 18, 22, 26, and 27 are generic to the following disclosed patentably distinct species: a compound that is a selective inhibitor for dopamine, serotonin, and norepinephrine.

Page 4

- 5. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 6. Claim 18 is generic to a plurality of disclosed patentably distinct species comprising Dyskinesia, Tardive Dyskinesia, Lingual Dyskinesia and Facial Dyskinesia. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.
- 7. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 8. Claims 26 and 27 are generic to a plurality of disclosed patentably distinct species comprising Dementia, Alzheimer's dementia, and non-Alzheimer's dementia.

Art Unit: 1614

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

- 9. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 10. A telephone call to the attorney is not required where: 1) the restriction requirement is complex, 2) the application is being prosecuted pro se, or 3) the examiner knows from past experience that a telephone election will not be made, see MPEP Sect. 812.01.
- 11. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. C. Jones whose telephone number is (703) 308-4634. The examiner can normally be reached on Mondays through Fridays from 8:30 am to 6:00 pm. The examiner can also be reached on alternate Mondays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Application/Control Number: 10/750,118 Page 6

Art Unit: 1614

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-

1235.

PRIMARY EXAMINER

Tech. Ctr. 1614

February 28, 2006

Continuation of Disposition of Claims: Claims subject to restriction and/or election requirement are 1,3,5-7,10,11,18,19,22,23,26-28 and 31-41.